Interní Med. 2008; 10(3): 134-137

Strategy of antithrombotic treatment in patients with atrial fibrillation

prof. MUDr. Jan Bultas CSc, MUDr. Debora Karetová CSc
II. interní klinika kardiologie a angiologie 1. LF UK a VFN, Praha

Atrial fibrillation and flutter are characterized by disorganization of impulse conduction in cardiac atria. It results in decreased contractility; blood stagnation activates hemostasis and increases risk of thromboembolic stroke. This risk is increased in patients after a stroke, diabetic patients, patients with hypertension, heart failure and older patients, in patients with postreumatic valve disease, coronary heart disease and females. According the risk antithrombotic treatment is indicated, especially anticoagulation treatment with warfarin. In consistence with guidelines strategy of treatment and frequent situations from daily practice are discussed.

Keywords: atrial fibrillation, atrial flutter, antithrombotic treatment, warfarin

Published: May 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bultas J, Karetová D. Strategy of antithrombotic treatment in patients with atrial fibrillation. Interní Med. 2008;10(3):134-137.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Andrews M, et al. Atrial fibrillation. Mt Sinai J Med. 2006; 73 (1): 482-492.
    2. Benjamin EJ, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998, 8; 98 (10): 946-952. Go to original source... Go to PubMed...
    3. ESC guidelines desk reference - Atrial Fibrilation, Compendium of ESC Guidelines, 2007: 259-277.
    4. Furberg CD, et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994, 1; 74(3): 236-241. Go to original source... Go to PubMed...
    5. Kopecky SL, et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med. 1987, 10; 317 (11): 669-674. Go to original source... Go to PubMed...
    6. Lloyd-Jones DM, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004; 31; 110(9): 1042-1046. Go to original source... Go to PubMed...
    7. Nieuwlaat R, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006; 27 (24): 3018-3026. Go to original source... Go to PubMed...
    8. Reynolds MW, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest. 2004; 126 (6): 1938-1945. Go to original source... Go to PubMed...
    9. Saxena R, et al. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke. 2001; 32 (10): 2333-2337. Go to original source... Go to PubMed...
    10. Scholten MF, et al. Anticoagulation in atrial fibrillation and flutter. Europace. 2005; 7 (5): 492-499. Go to original source... Go to PubMed...
    11. Suchopár J, et al. Kompendium lékových interakcí Infopharm, 2005 a 2007, Praha (publikace a PC program).
    12. Upshaw CB, et al. Hemodynamic changes after cardioversion of chronic atrial fibrillation, Arch Intern Med, 1997, 26; 157 (10): 1070-1076. Go to original source...
    13. Wyse DG, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002, 5; 347 (23): 1825-1833. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.